For patients with bladder cancer, invisible blood in urine may aid diagnosis
the ONA take:
According to new research published in the British Journal of General Practice, invisible blood in the urine may be able to be used to diagnose bladder cancer. Researchers at the University of Exeter Medical School in Exeter, United Kingdom, identified over 26,000 patients from the Clinical Practice Research Datalink and found that one in 60 patients over the age of 60 who had invisible blood in their urine were later diagnosed with bladder cancer.
The best known indicator of bladder cancer is visible blood in urine. Identifying invisible blood could boost early detection of bladder cancer, thereby improving outcomes compared with those who are diagnosed late.
According to the National Cancer Institute, if diagnosed with stage 1 bladder cancer, a patient has an 88% 5-year survival rate, but if diagnosed with stage 4 cancer, the 5-year survival rate drops to 15%.
The American Cancer Society says that nearly 75,000 Americans will be diagnosed with bladder cancer and about 16,000 will die from the disease in 2014. Bladder cancer is about three times more likely in men than women and occurs mainly in older adults.
Invisible blood in the urine may be able to be used to diagnose bladder cancer.
New research which finds that invisible blood in urine may be an early warning sign of bladder cancer is likely to shape guidelines for clinicians. Scientists at the University of Exeter Medical School found that one in 60 people over the age of 60 who had invisible blood in their urine (identified by their GP testing their urine) transpired to have bladder cancer.
The figure was around half those who had visible blood in their urine - the best known indicator of bladder cancer. However, it was still higher than figures for other potential symptoms of bladder cancer that warrant further investigation.
- FDA Grants Approval to Bevacizumab-awwb as First Biosimilar for Anticancer Therapy
- Efficacy of Octreotide LAR, Lanreotide in Management of Carcinoid Tumors
- Multivitamin Use May Reduce Risk of Chemo-Induced Neuropathy
- Overall Survival in Advanced Melanoma Improved With Nivolumab, Ipilimumab Combination
- Adjuvant Durvalumab Therapy May Prolong Progression-free Survival in NSCLC
- Invisible Burdens: The Complex Needs of Caregivers of Patients With Brain Cancer
- Cannabis Reduces Response Rate to Immunotherapy for Cancer
- Perioperative Blockade of Pathways May Improve Outcomes in Breast Cancer
- Zika Virus Preferentially Targets Glioblastoma Stem Cells
- Daratumumab Infusion-Related Reactions Managed by Pre/Postinfusion Medications
- Lorazepam Plus Haloperidol Improves Agitation in Cancer-Related Delirium
- Cost of Care Significantly Increased With Carcinoid Syndrome in NETs
- Treating Intractable Hiccups in Advanced Cancer, Palliative Care Setting
- Severe Mental Illness May Worsen Breast Cancer Survival Outcomes
- Imaging Management of Breast Density, a Controversial Risk Factor for Breast Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|